← ANALYST RATINGS · TIPRANKS
Abivax SA Sponsored ADR (ABVX): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy1 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $156, the highest $180, the lowest $118. The average is +77.5% from the last price of $88.13.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $175 | Buy | +98.6% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | −4.1%next day −3.1% · 5 days −7.7% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $180 | Buy | +104.2% | Reiterated | 28.09.26on TipRanks 07:15 | +7.1%next day +1.9% · 5 days −6.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $108 → $93.00−13.9% | Sell | +5.5% | Downgrade | 23.09.26on TipRanks 09:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $109 → $93.00−14.7% | Sell | +5.5% | Downgrade | 23.09.26on TipRanks 09:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $106 → $95.00−10.4% | Hold | +7.8% | Reiterated | 23.09.26on TipRanks 09:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $104 → $93.00−10.6% | Sell | +5.5% | Downgrade | 23.09.26on TipRanks 09:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $107 → $94.00−12.1% | Hold | +6.7% | Reiterated | 23.09.26on TipRanks 09:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $106 → $94.00−11.3% | Hold | +6.7% | Reiterated | 23.09.26on TipRanks 09:05 | — | |
| David Nierengarten★★★★★★★★★★#297 · hits 55% · avg +23.0% | Wedbush | $140 → $118−15.7% | Hold | +33.9% | Reiterated | 22.09.26on TipRanks 08:00 | −5.0%next day −3.5% · 5 days +1.4% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | $155 → $151−2.6% | Buy | +71.3% | Reiterated | 22.09.26on TipRanks 07:35 | −5.0%next day −3.5% · 5 days +1.4% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $170 → $168−1.2% | Buy | +90.6% | Reiterated | 22.09.26on TipRanks 07:10 | −5.0%next day −3.5% · 5 days +1.4% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $148 | Buy | +67.9% | Reiterated | 22.09.26on TipRanks 03:35 | −5.0%next day −3.5% · 5 days +1.4% | ↗ |
| Rajan Sharma★★★★★★★★★★#5820 · hits 52% · avg +1.9% | Goldman Sachs | $155 | Buy | +75.9% | Initiated | 09.09.26on TipRanks Sep 10 10:30 | +0.9%next day −2.3% · 5 days −13.3% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $165 → $175+6.1% | Buy | +98.6% | Assigned | 09.07.26on TipRanks 08:04 | +0.7%next day −1.0% · 5 days −2.0% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $175 | Buy | +98.6% | Reiterated | 01.07.26on TipRanks Jul 2 04:25 | −0.4%next day +9.3% · 5 days +5.4% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $158 | Buy | +79.3% | Upgrade | 01.07.26on TipRanks Jun 30 16:15 | −0.4%next day +9.3% · 5 days +5.4% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $176 → $136−22.7% | Buy | +54.3% | Assigned | 03.06.26on TipRanks 13:25 | +25.0%next day +16.0% · 5 days +12.6% | ↗ |
| Unknown Analyst | Leerink Partners | $140 | Buy | +58.9% | Reiterated | 02.06.26on TipRanks 08:35 | −44.2%next day +25.0% · 5 days +44.6% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $131 → $187+42.7% | Buy | +112.2% | Reiterated | 02.06.26on TipRanks 05:50 | −44.2%next day +25.0% · 5 days +44.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Abivax SA Sponsored ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 02.10.26: target $159 at a price of $95.10 (+66.9%); now: $156 at $88.13 (+77.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 13 | 13 | 13 | 7 | 8 |
| Buy | 18 | 18 | 22 | 13 | 6 | 1 |
| Hold | 0 | 3 | 4 | 4 | 2 | 1 |
| Sell | 2 | 2 | 2 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 14.12.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.96 (from $-1.44 to $-0.61). Last quarter: $-1.68.
Best top-analyst consensus in the sector · Healthcare
About Abivax SA Sponsored ADR
- CEO: Marc de Garidel
- Employees: 80
- 7-11 Boulevard Haussmann, Paris, IF, 75009, FR
- www.abivax.com
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Data from the stock’s TipRanks forecast page, read 106 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗